Recombinetics is a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine. Its gene-editing technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools that enable biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

Centro de Tecnologia Canavieira (English:Sugarcane Research Center) or CTC is the largest sugarcane technology center in the world. Its headquarters is located in Piracicaba, São Paulo in one of the most prosperous agribusiness regions in Brazil. CTC was founded in 1969 to attend the technological needs of Copersucar sugarcane producers. In 2004, the Sugarcane Research Center started offering innovation and technology also to sugarcane producers and processors associates all over Brazil. CTC became a S.A. company in 2011 and since then Copersucar and Raízen are the company majority owners.

Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Temasek Life Sciences Laboratory (TLL) was established in August 2002 and as a Singapore Non Profit Philanthropic Research Organisation focusing primarily on understanding the cellular mechanisms that underlie the development and physiology of plants, fungi and animals which provides foundation for biotechnology innovation.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well as agricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests.

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Oxford Biomedica (UK) Ltd., part of Oxford Biomedica Plc, is a company headquartered in Oxford, UK. The firm develops novel gene therapy products and treatment for cystic fibrosis.

Shenzhen Boao Kang Biotechnology Co., Ltd., established on 2013-11-04, Business scope includes general business items:Research on Biotechnology Products,Biological product,biotechnology products,Development of biochemical scientific research reagents and related technical services,Biochemical Research Instruments,Reagent,Sales of laboratory consumables;Operating Class II medical devices;Domestic Trade(Does not contain franchise,monopoly,Specially Controlled Commodities);Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:

Our vision is to provide a capital efficient and flexible platform where emerging companies can transform the scientific discoveries of today into the breakthrough healthcare products of tomorrow. To accelerate scientific discovery, business, financial and operational obstacles need to be removed so that companies can do what they do best, focus on the science and bringing innovative solutions to patients.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Shenzhen Huada Yinyuan Pharmaceutical Technology Co., Ltd., established on 2019-08-29, Business scope includes general business items:medical technology,Technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services;Diagnostic reagents,medicine(Diagnostic Reagents Regulated by Drugs),medical instruments,bioengineered drugs,natural medicine,traditional Chinese medicine,Plant extracts,R&D and technology transfer of intermediates;Technical consultation and technology transfer of medical achievements;Biotechnology Development Services;Biotechnology Extension Services;Biotechnology Consulting,Technical Services;Biotechnology Transfer Services;Consumables for biological research,Reagent,Wholesale and retail of instruments;computer software,Technology development and promotion of hardware and network systems;Operating import and export business,The licensing program is:Sales of Class II Medical Devices;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)